QuintilesIMS announces new business segments, share repurchase program

In its first quarter after the merger of Quintiles and IMS Health, the newly formed single company said it has kick-started a $1.5 billion repurchase of QuintilesIMS’s ($Q) outstanding common stock as it also forms new business units.

The repurchases, usually done to help boost the value of remaining shares on the market, should be completed by next year, according to the co’s statement.

The new entity was earlier this year meant to be valued at around $19 billion, but yesterday Quintiles IMS Holdings was worth $17.78 billion, with its share price falling steadily over the past month.

Virtual Roundtable

ESMO Post Show: Highlights From the Virtual Conference

Cancer experts and pharma execs will break down the headline-making data from ESMO, sharing their insights and analysis around the conference’s most closely watched studies. This discussion will examine how groundbreaking research unveiled over the weekend will change clinical practice and prime drugs for key new indications, and panelists will fill you in on the need-to-know takeaways from oncology’s hottest fields.

After announcing a re-jig of its exec team back in August, the firm has this week also created three new reporting segments: Commercial Solutions, Research & Development Solutions and Integrated Engagement Services.

The Commercial Solutions segment includes nearly all of the IMS legacy businesses as well as the Quintiles legacy real world late phase, payer/provider and advisory businesses.

The R&D Solutions segment includes much of the Quintiles legacy product development segment, and the Integrated Engagement Services segment includes most of Quintiles legacy contract sales organization businesses.

During its third quarter report, the combined company said its Q4 revenue guidance was $1.95 billion to $1.99 billion, with an adjusted diluted EPS of $1.04 to $1.08 per share. 

Suggested Articles

Clinical trial firm Phesi’s new report is some grim reading for the life science industry: Studies for new drugs are still suffering.

Tempus fugit: And time especially flies when it comes clinical trials. Covance is teaming up with the suitably named Tempus to clip its wings.

PPD has raised its quarterly guidance after weathering the COVID-19 storm and is immediately making a secondary offering of 38 million shares.